How Much Disease Remains After Ovarian Cancer Treatment? Small IMNN-001 Trial Releases Early Signals
Preliminary results from 18 evaluable patients show that adding locally delivered IL-12 gene therapy to chemotherapy and bevacizumab was associated with less microscopic residual disease and a higher circulating tumor DNA clearance rate; however, the sample is limited, and whether this can translate into delayed recurrence or longer survival remains to be answered by the complete trial and the Phase 3 study.